Status:
COMPLETED
Systematic Early Use of Neuromuscular Blocking Agents in ARDS Patients
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
ARDS
Eligibility:
All Genders
18-90 years
Phase:
PHASE4
Brief Summary
The use of neuromuscular blocking agents (NMBA) in ARDS patients has not been extensively investigated. The aim of the study is to show a reduction of the mortality rate of ARDS patients.
Detailed Description
The use of neuromuscular blocking agents (NMBA) in ARDS patients has not been extensively investigated. It has been recently demonstrated that a systematic 48-h infusion of NMBA is associated with a s...
Eligibility Criteria
Inclusion
- ARDS with a PaO2 / FiO2 \< 150 with a PEEP \> 5 since less than 48 hrs
- informed consent
Exclusion
- NMBA allergy
- Continuous administration of NMBA for ARDS prior inclusion
- Age \< 18 yrs
- SAPS II \> 70
- Persistent air leak
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2008
Estimated Enrollment :
340 Patients enrolled
Trial Details
Trial ID
NCT00299650
Start Date
March 1 2006
End Date
October 1 2008
Last Update
October 10 2008
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Réanimation polyvalente
Aix-en-Provence, France
2
Réanimation Polyvalente
Avignon, France
3
Hôpital Jean Minjoz - Réanimation médicale
Besançon, France
4
Hôpital Pellegrin - Réanimation médicale
Bordeaux, France, France